Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primary metabolites

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    374 result(s) found for: Primary metabolites. Displaying page 9 of 19.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2021-004927-34 Sponsor Protocol Number: KET01-02 Start Date*: 2022-03-28
    Sponsor Name:Ketabon GmbH
    Full Title: A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochlo...
    Medical condition: Treatment-resistant depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021003-24 Sponsor Protocol Number: 20100754 Start Date*: 2011-07-28
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dys...
    Medical condition: Acute heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) GB (Completed) LT (Completed) FI (Prematurely Ended) SK (Completed) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002122-67 Sponsor Protocol Number: 1211 Start Date*: 2013-12-05
    Sponsor Name:EORTC
    Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
    Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004445-36 Sponsor Protocol Number: LuDO-N Start Date*: Information not available in EudraCT
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma.
    Medical condition: Primary refractory or relapsed high-risk neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005169-36 Sponsor Protocol Number: NKV110721 Start Date*: 2008-02-07
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: NKV110721, A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting
    Medical condition: Prevention of nausea and vomiting due to first cycle of oxaliplatin based chemotherapy in patients with colorectal cancer receiving a combination with 5-fluorouracil and leucovorin, or in combinati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-004471-39 Sponsor Protocol Number: IMR-SCD-301 Start Date*: 2020-06-24
    Sponsor Name:IMARA, Inc.
    Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003008-42 Sponsor Protocol Number: ZN-d5-003 Start Date*: 2021-12-22
    Sponsor Name:K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
    Full Title: A Single-Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
    Medical condition: Relapsed or Refractory Light-Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2014-004010-28 Sponsor Protocol Number: I3Y-MC-JPBO Start Date*: 2015-03-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
    Medical condition: Brain tumors, Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002954-21 Sponsor Protocol Number: QBGJ398-201 Start Date*: 2020-05-06
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2
    Medical condition: Achondroplasia in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004803-36 Sponsor Protocol Number: 1199.13 Start Date*: 2009-03-30
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy i...
    Medical condition: stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) DK (Completed) LT (Completed) ES (Completed) SK (Completed) GB (Completed) FR (Completed) PT (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000541-31 Sponsor Protocol Number: 200807 Start Date*: 2016-12-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evalu...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) SE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001580-11 Sponsor Protocol Number: LuAA21004_305 Start Date*: 2009-04-09
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) NL (Completed) LV (Completed) LT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000023-15 Sponsor Protocol Number: H7T-MC-TAAL Start Date*: 2005-02-10
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
    Medical condition: Reduction of atherothrombotic events in patients with acute coronary syndromes (ACS) that is patients with ST-segment elevation MI [STEMI], non-ST-segment elevation MI [NSTEMI], or unstable angina...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) HU (Completed) CZ (Completed) SK (Completed) DE (Completed) IT (Completed) LT (Completed) EE (Completed) LV (Completed) IS (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000344-67 Sponsor Protocol Number: DCR-PHXC-104 Start Date*: 2020-08-07
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hype...
    Medical condition: Primary Hyperoxaluria Type 3
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000542-65 Sponsor Protocol Number: 200808 Start Date*: 2016-11-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to ...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) AT (Prematurely Ended) CZ (Completed) DE (Completed) PT (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) GR (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004630-41 Sponsor Protocol Number: H6Q-MC-JCBJ Start Date*: 2006-04-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
    Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) IT (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004093-40 Sponsor Protocol Number: 08-PIR-03 Start Date*: Information not available in EudraCT
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, ...
    Medical condition: Refractory Solid Tumors (Colorectal Cancer) Tumores sólidos refractarios (Cáncer colorrectal)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer LLT
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002619-89 Sponsor Protocol Number: B1761031 Start Date*: 2019-06-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR...
    Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000091-24 Sponsor Protocol Number: TAK-442 202 Start Date*: 2008-12-02
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
    Medical condition: acute coronary syndromes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) EE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-000455-12 Sponsor Protocol Number: SU-G-01 Start Date*: 2021-03-05
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis
    Medical condition: Grass pollen-induced allergic rhinoconjunctivitis for two years or more with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed) CZ (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:19:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA